BioSpace News Archive

Genestack Ltd. announced that its flagship multi-omics data catalog, curation and integrative search product, Omics Data Manager, has been licensed and implemented by a world-leading genomics research centre, the Wellcome Sanger Institute.

Financing led by Petrichor Healthcare Capital Management strengthens company’s global position as a leader in precision oncology and the field of Targeted Radionuclide Therapy

Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes, announced that members of its management will be attending the upcoming SVB Leerink Biopharma Private Company Connect Event.

Pulmonary Disease Expert, Dr. Susan Garwood, is Hosted by CHEST to Discuss Standardized Risk Assessment to Enhance Referral Patterns for Patients with Lung Nodules

Quest Diagnostics Incorporated, the world’s leading provider of diagnostic information services, announced financial results for the first quarter ended March 31, 2021.

Evelo Biosciences, a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, April 29, 2021 to report its first quarter 2021 financial results and discuss business highlights.

Kings Group, Kraig’s joint venture partner, leads branding, with unique trademarks centered on spider silk

Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced that it will host its virtual R&D Day for analysts and investors at 10:00 a.m. – 1:00 p.m. ET on Wednesday, April 28, 2021.

Designed for TLIF procedures, the 3D-printed FORZA Ti Spacer System further expands the comprehensive line of PEEK, PTC, and now Titanium interbody solutions offered by Orthofix for transforaminal lumbar applications

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the following upcoming oral presentation at the DDW 2021 regarding AXA1665, the company’s product candidate for the reduction in risk of recurrent overt hepatic encephalopathy (OHE):